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The main objective of this in vitro study was to assess the effects of cefotaxime and
ceftriaxone in killing Salmonella typhi in infected humanmacrophages. Humanmonocyte-
derived macrophages isolated from peripheral blood of human volunteers were cultured
in vitro for macrophage differentiation, and subsequently infected with S. typhi strains (a
clinical isolate and a standard strain TA-42) at a cell ratio of 10 : 1. MICs of cefotaxime and
ceftriaxone were determined by broth microdilution, and the antibiotics were included in
the culture medium at one and ﬁve times their MIC values. Samples of cell culture
medium taken at 0, 3, 6 and 24 h of incubation were cultured for growth of S. typhi on
nutrient agar. Gentamicin (10mg/L) was included in each well except for the control
wells, in order to prevent growth of extracellular S. typhi. Both antibiotics showed good in
vitro antibacterial effects against S. typhi strains. There were no statistically signiﬁcant
differences between the extracellular and intracellular effects of antibiotics with regard to
elimination of the bacteria. Cefotaxime and ceftriaxone are highly effective against
extracellular bacterial growth. The results of our in vitro experiments suggest that
cefotaxime and ceftriaxone might also be used clinically against susceptible intracellular
pathogens such as S. typhi.
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INTRODUCTION
Typhoid fever is still a major public health pro-
blem associated with signiﬁcant morbidity and
mortality in many countries [1]. Clinically, the
cardinal features of the infection arise as a result
of gastrointestinal disturbance, which follows
inﬁltration of the microorganism into the intestinal
mucosa. Salmonella species penetrate the intestinal
mucus layer through bacteria-induced endocyto-
sis. Thereafter, a similar process also takes place in
the infection of mucosa-associated tissue cells, in
particular the macrophages, a step which is clearly
important in the pathogenesis of typhoid fever [2].
Salmonellae survive and may also replicate within
the phagolysosome [3,4].
In the treatment of typhoid fever, the choice of
an antimicrobial agent requires consideration
of the current understanding of the behavior of
intracellular salmonellae. Thus, both effective
penetration into cells and resistance to environ-
mental conditions are important prerequisites for
the antibiotics to be effective. It has been shown
that the treatment of typhoid fever and, most
importantly, the chronic carriers of Salmonella typhi
with certain antibiotics is ineffective despite good
in vitro activity, since salmonellae within phago-
lysosomes create an acidic and viscous environ-
ment which causes antimicrobials to be less
effective and even inactive [1,5].
Here, we studied the efﬁcacy of cefotaxime and
ceftriaxone in killing S. typhi in human monocyte-
derived macrophages infected in vitro with a
standard and a clinical Salmonella isolate.
MATERIALS AND METHODS
Bacteria
A standard strain of S. typhi—42 TA(2-1)—
was obtained from Reﬁk Saydam Public Health
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Institute, Ankara, and a clinical strain isolated
from a fecal specimen was obtained from the
Bacteriology Section of the Central Laboratory at
the Ondokuz Mayis University Hospital, Samsun.
Strains were stored in brain–heart infusion (BHI)
(Difco, Detroit, MI, USA) broth containing 20%
glycerol at 70 8C, until used.
Human monocyte-derived macrophages
Human monocyte-derived macrophages were
obtained by the Ficoll–Hypaque density gradient
method and cultured as described elsewhere [6,7].
Monocytes were obtained from the blood of
healthy human volunteers, serologically negative
for hepatitis, syphilis, HIV and typhoid fever, and
without a history of vaccination against typhoid
fever [1]. Isolated monocytes were seeded into T25
tissue-culture ﬂasks and incubated with RPMI
1640 (Sigma, St Louis, MO, USA) with 10% fetal
calf serum (FCS) (Sigma) to form monolayers at
37 8C in a 5% CO2 humidiﬁed incubator for 7–12
days. The medium was replaced every three days.
Determination of minimal inhibitory
concentration (MIC)
The antibiotics used in this study were cefotaxime
and ceftriaxone, obtained from Eczacibasi, Istan-
bul, and gentamicin, fromBilimCo., Istanbul. They
were dissolved in solvents as recommended by the
manufacturers. MIC testing was performed by the
macrodilution method in Mueller–Hinton broth
(MHB) (Difco) supplied with Ca2þ and Mg2þ
cations [8,9].
Infection of macrophages
Macrophagemonolayers were removedwith a cell
scraper from the surface of culture ﬂasks by treat-
ingwith ice-cold 0.02%EDTA/PBS for 10min. Cell
viability was >90% as determined by the trypan
blue exclusion test [6].
Macrophages were seeded in 96-well plates at
105 cells/mL one night before infection with S.
typhi strains. They were incubated for one night
at 37 8C in a humidiﬁed 5% CO2 incubator. After
replacement of the medium, the macrophages in
the 96-well plates were infected with 106CFU/mL
of the S. typhi strains (opsonized with 10% normal
human serum for 30min at 37 8C) at a ratio of 10
bacteria/1 macrophage. Plates were rotated at
200 rev/min for 5min at room temperature, prior
to incubation for 30min at 37 8C for phagocytosis
to occur. At the end of phagocytosis, the cells were
washed with PBS to remove non-phagocytosed
bacteria [1,7,10–12]. The cells were then incubated
with fresh maintenance medium (RPMI with 5%
FCS) containing gentamicin (10mg/L) to prevent
extracellular bacterial growth [1,11]. Antibiotics
were added at one and ﬁve times the MIC to each
well except for control wells. Macrophages were
not included in the wells when the extracellular
activities of the antibiotics were tested.
Samples
Wells were sampled at 0, 3, 6 and 24 h after infec-
tion. After washing wells twice with PBS to
remove all the gentamicin, the macrophages were
lyzed with 0.5% sodium deoxycholate, and the
samples were pooled [4,7,10]. Of these lysates,
100 mL was plated on an agar base to determine
the number of CFUs [13].
Statistics
The results were tested for signiﬁcance using Stu-
dent’s t-test and the chi-square test.
RESULTS
The MIC values of cefotaxime and ceftriaxone are
summarized in Table 1; the MICs of ceftriaxone
against the standard strain and the clinical isolate
differed by one dilution.
The effects of cefotaxime and ceftriaxone at MIC
and 5MIC on S. typhi, both inside and outside
macrophages, are summarized in Figures 1–4. In a
control experiment, gentamicin did not exhibit any
signiﬁcant inhibitory effect on intracellular Salmo-
nella typhi (data not shown). On the other hand,
both cephalosporins at MIC and 5MIC showed
similar effects in the macrophage monolayers
Table 1 MIC values of cefotaxime and ceftriaxone against
Salmonella typhi
MIC (mg/L)
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infected with both strains. Some killing took place
in the ﬁrst 3 h, whereas their maximum efﬁciencies
were attained at 6–24 h. On the other hand, as
shown in Figures 1 and 2, the clinical strain appea-
red to be more resistant than the standard strain,
especially at 5MIC of cefotaxime (P< 0.05). The
effects of antibiotics on both strains in wells with-
out macrophages were similar (P> 0.05) (Figures 3
and 4).
DISCUSSION
To spread and cause infection, S. typhi needs to
invade a macrophage, survive within it and be res-
istant to thebactericidal effects ofmacrophages [14].
For treating a disease caused by an intracellular
pathogen, the antibiotics must have good penetra-
tion ability and effective killing capacity, in order
to treat intracellularly infected cells. In countries
like India, Pakistan and Vietnam, drug resistance
is a common problem [15,16]. Treatments of S.
typhi infections with ampicillin, chloramphenicol
and trimethoprim-sulfamethoxasole, which pene-
trate cells well, have been used for years. How-
ever, increasing resistance to these drugs has
necessitated the search for alternative drugs.
Now new quinolones and third-generation cepha-
losporins, including cefotaxime and ceftriaxone,
are successfully used in clinical practice [15–17].
In the present study, we compared the intracel-
lular and extracellular effects of cefotaxime and
ceftriaxone on S. typhi, both inside and outside
macrophages.
Both antibiotics had good effects on the stan-
dard strain, especially at 5MIC within macro-
phages (P< 0.05), but outside macrophages they
had similar effects at both concentrations (Figures
2 and 3). Maximum efﬁciencies of antibiotics were
observed at 6 and 24 h at MIC.
We found that antibiotics had different efﬁcien-
cies in intracellular and extracellular environ-
ments, especially with regard to the clinical
strain. For example, at the end of 24 h, the extra-
cellular effects of antibiotics on the clinical strain
were better than the intracellular effects (P< 0.05),
except for ceftriaxone at 5MIC. Ceftriaxone had
similar effects on the clinical isolates inside and
outside macrophages. The extracellular and intra-
cellular activities of both antibiotics did not differ
when tested against the standard strain (P> 0.05).
Chang et al. [1] reported that cefotaxime and
ceftriaxone exhibit good intracellular effects,
Figure 1 Effects of cefotaxime (ctx) and ceftriaxone (cro) on
the standard strain within macrophages. 5MIC.
Figure 2 Effects of cefotaxime (ctx) and ceftriaxone (cro) on
the clinical strain within macrophages. 5MIC.
Figure 3 Effects of cefotaxime (ctx) and ceftriaxone (cro) on
the standard strain without macrophages. 5MIC.
Figure 4 Effects of cefotaxime (ctx) and ceftriaxone (cro) on
the clinical strain without macrophages. 5MIC.
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despite the well known poor concentrating ability
of penicillins and cephalosporins inside polymor-
phonuclear leukocytes [1]. Our results are in agree-
ment with their results, and further suggest that
these antibiotics are able to enter macrophages to
act on S. typhi intracellularly. Furthermore, it has
been shown that cephalosporins are able to kill
phagocytosed Staphylococcus aureus when the kill-
ing mechanisms of monocytes have been blocked
[18].
Finally, our in vitro study suggests that third-
generation cephalosporins (cefotaxime and cef-
triaxone) have good intracellular effects against
S. typhi, which suggests that they might be used
when resistance to chloramphenicol or ampicillin
is experienced.
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